Relevant bibliographies by topics / 37-38 / Journal articles
To see the other types of publications on this topic, follow the link: 37-38.

Journal articles on the topic '37-38'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '37-38.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Pasch, Heiner. "Lohnen die EBM-Kapitel 37 und 38?" DNP - Der Neurologe und Psychiater 17, no. 7-8 (August 2016): 58. http://dx.doi.org/10.1007/s15202-016-1371-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Baffes, Melanie. "Christology and Discipleship in John 7:37-38." Biblical Theology Bulletin: Journal of Bible and Culture 41, no. 3 (June 13, 2011): 144–50. http://dx.doi.org/10.1177/0146107911413211.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mildenberger, Irene. "Joh 19, (31-37) 38-42 30.3.2013 Karsamstag." Pastoraltheologie 102, no. 2 (January 2013): 185–89. http://dx.doi.org/10.13109/path.2013.102.2.185.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Yu, Zhiyan, Jun Liu, Rui Zhang, Xinmei Huang, Tiange Sun, Yueyue Wu, Brett D. Hambly, and Shisan Bao. "IL-37 and 38 signalling in gestational diabetes." Journal of Reproductive Immunology 124 (November 2017): 8–14. http://dx.doi.org/10.1016/j.jri.2017.09.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

&NA;. "Interleukin-4-38-37-PE38KDEL gains orphan drug status." Inpharma Weekly &NA;, no. 1643 (June 2008): 22. http://dx.doi.org/10.2165/00128413-200816430-00061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Polcaro, V. F., and L. Norci. "The HMXRB system BD+37° 1160/4U 0515+38." Advances in Space Research 28, no. 2-3 (January 2001): 395–98. http://dx.doi.org/10.1016/s0273-1177(01)00437-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Nicol, Martin. "Lk 1,26–33(34–37)38 18.12.2016 4. Advent." Göttinger Predigtmeditationen 71, no. 1 (October 2016): 36–42. http://dx.doi.org/10.13109/gpre.2016.71.1.36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nicol, Martin. "Lk 1,26–33(34–37)38 18.12.2016 4. Advent." Pastoraltheologie 105, no. 11 (November 2016): 36–42. http://dx.doi.org/10.13109/path.2016.105.11.36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Jae-Sung Kim. "Rivers of Living Water - John 4:14; 7:37-38." THEOLOGICAL THOUGHT ll, no. 187 (December 2019): 5–8. http://dx.doi.org/10.35858/sinhak.2019..187.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Yu, Chen, and Wei Hong. "37-38 GHz substrate integrated filtenna for wireless communication application." Microwave and Optical Technology Letters 54, no. 2 (December 15, 2011): 346–51. http://dx.doi.org/10.1002/mop.26589.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

DEVILLERS, Olivier. "Le discours d'Othon à ses troupes (Tacite,Histoires, I, 37-38)." Vita Latina 168 (May 1, 2003): 30–37. http://dx.doi.org/10.2143/vl.168.0.583266.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Kunz, Ralph. "Hebr 10,35-36(37-38)39 5.10.2014 16. Sonntag nach Trinitatis." Göttinger Predigtmeditationen 68, no. 4 (July 2013): 446–51. http://dx.doi.org/10.13109/gpre.2013.68.4.446.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Crump, Casey, Kristina Sundquist, Marilyn A. Winkleby, and Jan Sundquist. "Early-term Birth (37–38 Weeks) and Mortality in Young Adulthood." Epidemiology 24, no. 2 (March 2013): 270–76. http://dx.doi.org/10.1097/ede.0b013e318280da0f.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Kunz, Ralph. "Hebr 10,35-36(37-38)39 5.10.2014 16. Sonntag nach Trinitatis." Pastoraltheologie 103, no. 8 (July 2014): 446–51. http://dx.doi.org/10.13109/path.2014.103.8.446.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Tanne, J. H. "Babies born at 37-38 weeks lag academically eight years later." BMJ 345, jul05 1 (July 5, 2012): e4567-e4567. http://dx.doi.org/10.1136/bmj.e4567.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Lödel, Ruth. "4. Advent – 18. 12. 2016 Lukas 1,26–33(34–37)38." Homiletische Monatshefte 92, no. 1 (January 2017): 15–19. http://dx.doi.org/10.13109/homh.2017.92.1.15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Reddy, Uma, Chia-Wen Ko, and Marian Willinger. "“Early” term births (37-38 weeks) are associated with increased mortality." American Journal of Obstetrics and Gynecology 195, no. 6 (December 2006): S202. http://dx.doi.org/10.1016/j.ajog.2006.10.725.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Mahmud, Kuasha, KM Nasiruddin, MA Hossain, and L. Hassan. "Screening sugarcane somaclones and their parent varieties against red rot (Colletotrichum falcatum) and assessment of Variability by RAPD and SSR markers." SAARC Journal of Agriculture 13, no. 2 (January 25, 2016): 173–82. http://dx.doi.org/10.3329/sja.v13i2.26578.

Full text
Abstract:
The experiment was conducted to find out red rot disease causing pathogenic reactions of somaclones (R0) and their respective parents at BSRI farm in the cropping season 2011-2012. A total number of sugarcane genotypes 24 including 4 sugarcane varieties viz. Isd 37, Isd 38, Isd 39 and also Isd 40 were inoculated to screen red rot resistant levels (R = Resistant, MR = Moderately Resistant) to susceptible levels (S = Susceptible, MS = Moderately Susceptible, HS = Highly Susceptible) after 7 months of planting. As a result, Isd 37 variety (source/parent) and its somaclones CC–37–12 and CC–37–86 were found to be resistant while 7 somaclones showed moderately resistant reaction. Furthermore, somaclones of Isd 38 variety viz. CC–38–2 as moderately resistant, CC–38–10 as moderately susceptible and also CC–11(38)–8 as susceptible reaction were recorded while Isd 38 variety showed resistant reaction. On the other hand, Isd 39 and Isd 40 source varieties with their somaclones were found as resistant reaction against red rot pathogen. Some somaclones showed different reaction from their source varieties such as moderately resistant somaclones were obtained from resistant source variety Isd 37 while somaclones CC–38–2 as moderately resistant, CC–38–10 as moderately susceptible and somaclone CC–38–8 as susceptible were obtained from resistant source variety Isd 38 against red rot pathogens respectively. Besides, some somaclones showed similar reaction from their resistant source varieties Isd 37, Isd 39 and also Isd 40. It revealed that reaction against red rot pathogen, induced somaclones showed variation with their source varieties. Red rot resistance somaclones were isolated and assessed for the presence of variability through RAPD and SSR markers. Cluster and sub cluster formation verified the presence of variability in the red rot resistance somaclones with respect to the parent.SAARC J. Agri., 13(2): 173-182 (2015)
APA, Harvard, Vancouver, ISO, and other styles
19

Karrer, Martin. "Hebräer 10, 35–36 (37–38) 39 7.9.2008 16. Sonntag nach Trinitatis." Göttinger Predigtmeditationen 62, no. 4 (July 2007): 393–99. http://dx.doi.org/10.13109/gpre.2007.62.4.393.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Döhling, Jan-Dirk. "Lukas 1, 26-33 (34-37) 38 19.12.2010 4. Sonntag im Advent." Göttinger Predigtmeditationen 65, no. 1 (October 2010): 34–40. http://dx.doi.org/10.13109/gpre.2010.65.1.34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Craik, T. W. "New Nuts or Hazel Nuts? A Midsummer Night's Dream, IV.i.37-38." Notes and Queries 59, no. 4 (November 27, 2012): 533–34. http://dx.doi.org/10.1093/notesj/gjs146.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Boyle, Brian. "Narrative as Ideology: Synchronic (Narrative Critical) and Diachronic Readings of Jeremiah 37–38." Pacifica: Australasian Theological Studies 12, no. 3 (October 1999): 293–312. http://dx.doi.org/10.1177/1030570x9901200305.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Nahm, Moon H., W. Winn Chatham, and William H. Benjamin. "Device for Carrying Blood Samples at 37°C for Cryoglobulin Test." Clinical and Vaccine Immunology 19, no. 9 (July 18, 2012): 1555–56. http://dx.doi.org/10.1128/cvi.00295-12.

Full text
Abstract:
ABSTRACTTo reliably transport blood samples for cryoglobulin analysis, we have created a sample transport device containing a mixture of two waxes that solidifies at 38°C and maintains sample temperature at 38°C. Samples arriving at the laboratory at 37 to 38°C increased to 95% from 34% with the use of the device.
APA, Harvard, Vancouver, ISO, and other styles
24

Boutet, Marie-Astrid, Alessandra Nerviani, and Costantino Pitzalis. "IL-36, IL-37, and IL-38 Cytokines in Skin and Joint Inflammation: A Comprehensive Review of Their Therapeutic Potential." International Journal of Molecular Sciences 20, no. 6 (March 13, 2019): 1257. http://dx.doi.org/10.3390/ijms20061257.

Full text
Abstract:
The interleukin (IL)-1 family of cytokines is composed of 11 members, including the most recently discovered IL-36α, β, γ, IL-37, and IL-38. Similar to IL-1, IL-36 cytokines are initiators and amplifiers of inflammation, whereas both IL-37 and IL-38 display anti-inflammatory activities. A few studies have outlined the role played by these cytokines in several inflammatory diseases. For instance, IL-36 agonists seem to be relevant for the pathogenesis of skin psoriasis whereas, despite being expressed within the synovial tissue, their silencing or overexpression do not critically influence the course of arthritis in mice. In this review, we will focus on the state of the art of the molecular features and biological roles of IL-36, IL-37, and IL-38 in representative skin- and joint-related inflammatory diseases, namely psoriasis, rheumatoid arthritis, and psoriatic arthritis. We will then offer an overview of the therapeutic potential of targeting the IL-36 axis in these diseases, either by blocking the proinflammatory agonists or enhancing the physiologic inhibitory feedback on the inflammation mediated by the antagonists IL-37 and IL-38.
APA, Harvard, Vancouver, ISO, and other styles
25

Balogh, Orsolya, Alice Berger, Aldona Pieńkowska-Schelling, Florian Willmitzer, Paula Grest, Fredi Janett, Claude Schelling, and Iris M. Reichler. "37,X/38,XY Mosaicism in a Cryptorchid Bengal Cat with Müllerian Duct Remnants." Sexual Development 9, no. 6 (January 16, 2016): 327–32. http://dx.doi.org/10.1159/000443233.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

He, Xingyao, Nundia Louis, Peng Zhang, Irina Balyasnikova, Craig Horbinski, Stewart Goldman, and Rintaro Hashizume. "PDTM-37. NEW THERAPEUTIC APPROACH FOR BRAINSTEM GLIOMA: INTRANASAL DELIVERY OF NANOLIPOSOMAL SN-38." Neuro-Oncology 19, suppl_6 (November 2017): vi197—vi198. http://dx.doi.org/10.1093/neuonc/nox168.800.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

座長：片田, 彰博. "O-6群 鼻呼吸障害（演題：O-37・O-38）." Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology) 60, no. 3 (2021): 326. http://dx.doi.org/10.7248/jjrhi.60.326.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Martínez, Raúl Antonio. "Las relaciones interpersonales en la empresa." Realidad Empresarial, no. 3 (April 28, 2017): 37–38. http://dx.doi.org/10.5377/reuca.v0i3.5999.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Barbanti, Sinara. "Relação de pareceristas ad hoc (2019)." Resgate: Revista Interdisciplinar de Cultura 27, no. 2 (December 19, 2019): 215–20. http://dx.doi.org/10.20396/resgate.v27i2.8657941.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Bhattarai, Hari Krishna. "Neonatal mortality in Nepal: A Public Health Concern." Health Prospect 10 (July 22, 2018): 37–38. http://dx.doi.org/10.3126/hprospect.v10i0.5648.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Papathanasiou, E., P. Conti, F. Carinci, D. Lauritano, and T. C. Theoharides. "IL-1 Superfamily Members and Periodontal Diseases." Journal of Dental Research 99, no. 13 (August 6, 2020): 1425–34. http://dx.doi.org/10.1177/0022034520945209.

Full text
Abstract:
Periodontitis is a complex, multifactorial chronic disease involving continuous interactions among bacteria, host immune/inflammatory responses, and modifying genetic and environmental factors. More than any other cytokine family, the interleukin (IL)–1 family includes key signaling molecules that trigger and perpetuate periodontal inflammation. Over the years, the IL-1 family expanded to include 11 members of cytokines, some with agonist activity (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, and IL-36γ), receptor antagonists (IL-1Ra, IL-36Ra), and 2 anti-inflammatory cytokines (IL-37, IL-38). The IL-1 receptor antagonist (IL-1Ra) has emerged as a pivotal player in the defense against periodontitis. IL-33 primarily induces the production of Th2-associated cytokines but acts as an “alarmin” via stimulation of mast cells. The IL-36 subclass of cytokines may be important in regulating mucosal inflammation and homeostasis. IL-37 suppresses innate and acquired immune responses. IL-38 is the most recent member of the IL-1 superfamily and has anti-inflammatory properties similar to those of IL-37 but through different receptors. However, limited evidence exists regarding the role of IL-37 and IL-38 in periodontitis. Despite the development of IL-1 blocking agents, therapeutic blockade of select IL-1 family members for periodontitis has only been partially investigated in preclinical and clinical research, while the development of IL-37 and IL-38 as novel anti-inflammatory drugs has not been considered adequately. Here, we review the key properties of the IL-1 family members and provide insights into targeting or promoting select cytokines as new therapeutic agents.
APA, Harvard, Vancouver, ISO, and other styles
32

Moo-Penn, W. F., D. C. Swan, T. K. Hine, R. M. Baine, D. L. Jue, J. M. Benson, M. H. Johnson, D. M. Virshup, and W. H. Zinkham. "Hb Catonsville (glutamic acid inserted between Pro-37(C2)α and Thr-38(C3)α)." Journal of Biological Chemistry 264, no. 36 (December 1989): 21454–57. http://dx.doi.org/10.1016/s0021-9258(20)88202-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

IZUMIKAWA, Miho, Shams Tabrez KHAN, Hisayuki KOMAKI, Aya NAGAI, Shigeki INABA, Motoki TAKAGI, and Kazuo SHIN-YA. "JBIR-37 and -38, Novel Glycosyl Benzenediols, Isolated from the Sponge-Derived Fungus,Acremoniumsp. SpF080624G1f01." Bioscience, Biotechnology, and Biochemistry 73, no. 9 (September 23, 2009): 2138–40. http://dx.doi.org/10.1271/bbb.90346.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

KRISHNARAJ, MOOTHEDATHU. "A New Combination in Phanera Lour. (Cercideae: Caesalpinioideae: Leguminosae)." Phytotaxa 183, no. 4 (October 24, 2014): 284. http://dx.doi.org/10.11646/phytotaxa.183.4.8.

Full text
Abstract:
In four recent publications (Wunderlin 2011, Bandyopadhyay et al. 2012, Bandyopadhyay 2013, Mackinder & Clark 2014), altogether seventy-two new combinations have been made in Phanera Loureiro (1790: 37–38) from the Old World because the subgenus Phanera Loureiro (1790: 37–38) (see Wunderlin et al. 1987, Bandyopadhyay 1999) under Bauhinia Linnaeus (1753: 374) is recognized as a genus distinct from the latter based on recent advances in molecular phylogeny (Lewis &Forest 2005, Bruneau et al. 2008, Sinou et al. 2009). I have proposed here one more new combination in Phanera as follows.
APA, Harvard, Vancouver, ISO, and other styles
35

Kutubi, Afroza. "Professionalism in Medical Practice." Journal of Shaheed Suhrawardy Medical College 8, no. 2 (July 5, 2018): 37–38. http://dx.doi.org/10.3329/jssmc.v8i2.37240.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Ferreira Bogado, Miguel, and María Nilda Mosqueira Lara. "DUODENAL SOMATOSTATINOMA." CIRUGIA PARAGUAYA 41, no. 3 (December 30, 2017): 37–38. http://dx.doi.org/10.18004/sopaci.diciembre.37-38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Bowers, Katherine, Jane Khoury, and Tetsuya Kawakita. "Nonmedically Indicated Induction of Labor Compared with Expectant Management in Nulliparous Women Aged 35 Years or Older." American Journal of Perinatology 36, no. 01 (May 3, 2018): 045–52. http://dx.doi.org/10.1055/s-0038-1648228.

Full text
Abstract:
Objective This article compares maternal and neonatal outcomes in women aged ≥ 35 years who experienced nonmedically indicated induction of labor (NMII) versus expectant management. Study Design This was a retrospective cohort study of nulliparas aged ≥ 35 years with a singleton and cephalic presentation who delivered at term. Outcomes were compared between women who underwent NMII at 37, 38, 39, and 40 weeks' gestation and those with expectant management that week. Adjusted odds ratios (aORs) with 95% confidence intervals (95% CIs) were calculated, controlling for predefined covariates. Results Of 3,819 nulliparas aged ≥ 35 years, 1,409 (36.9%) women underwent NMII. Overall at 39 weeks' gestation or later, maternal and neonatal outcomes were similar or improved with NMII. At 37, 38, and 39 weeks' gestation, NMII compared with expectant management was associated with decreased odds of cesarean delivery at 37, 38, and 39 weeks' gestation. At 40 weeks' gestation, NMII compared with expectant management was associated with an increased odds of operative vaginal delivery and a decreased odds of neonatal intensive care unit (NICU) admission. Conclusion In nulliparous women aged ≥ 35 years, NMII was associated with decreased odds of cesarean delivery at 37 to 39 weeks' gestation and decreased odds of NICU admission at 40 weeks' gestation compared with expectant management.
APA, Harvard, Vancouver, ISO, and other styles
38

Harper, Judith A. "Citation accuracy in the Canadian Journal of Plant Science." Canadian Journal of Plant Science 72, no. 2 (April 1, 1992): 487–88. http://dx.doi.org/10.4141/cjps92-061.

Full text
Abstract:
A check of 5% of the citations in the bibliographies of articles in Canadian Journal of Plant Science, volumes 37–38 (1957–1958) and 69–70 (1989–1990), for accuracy identified errors in approximately 38% of the citations.Key words: Citations, references, errors, plant science
APA, Harvard, Vancouver, ISO, and other styles
39

Thapa, Parineeta, and Balkrishna Bhattarai. "Inadvertent arterial cannulation during intravenous cannulation of the cephalic vein." Journal of Society of Anesthesiologists of Nepal 2, no. 1 (October 1, 2015): 37–38. http://dx.doi.org/10.3126/jsan.v2i1.13558.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Ji, Chao Hui, Cheng Wu Tang, Wen Ming Feng, Ying Bao, and Li Qin Yao. "A Chinese Herbal Decoction, Huoxue Qingyi Decoction, Promotes Rehabilitation of Patients with Severe Acute Pancreatitis: A Retrospective Study." Evidence-Based Complementary and Alternative Medicine 2016 (2016): 1–5. http://dx.doi.org/10.1155/2016/3456510.

Full text
Abstract:
Severe acute pancreatitis (SAP) still remains an important surgical problem with high morbidity and mortality. The utilization of Traditional Chinese Medicine shows good prospects in therapy of SAP since it has advantages of more extensive pharmacological effects and fewer adverse effects. In this retrospective study, 38 patients received standardized treatment (control group) and 37 patients received Chinese herbal decoction, Huoxue Qingyi Decoction (HQD group), in addition to standard treatment for SAP. We found that the HQD group had a shorter hospital stay and lower initial expense than the control group (P<0.05). The duration of hyperamylasemia and systemic inflammatory response syndrome (SIRS) were significantly shorter in HQD group (P<0.05). The percentage of patients having any complication was much lower in HQD group than control group (27/38 versus 17/37,P<0.05), especially pancreatic pseudocyst (10/38 versus 2/37,P<0.05). No adverse effect induced by HQD was found. We concluded that the HQD was effective, safe, and economic for reduction of complication, for early recovery from systemic inflammation, and for promoting earlier rehabilitation from SAP.
APA, Harvard, Vancouver, ISO, and other styles
41

Rezende, Elcio Nacur. "Apresentação." Veredas do Direito: Direito Ambiental e Desenvolvimento Sustentável 17, no. 38 (September 16, 2020): 7–10. http://dx.doi.org/10.18623/rvd.v17i38.1932.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Wang, Jia, Ji-jun Yuan, Juan Mu, Qing Li, Nan Mou, Zhen-xing Yang, Wei Li, et al. "Humanized CD19 CAR-T Cell Combined with Multiple Combination Treatments in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma." Blood 134, Supplement_1 (November 13, 2019): 5346. http://dx.doi.org/10.1182/blood-2019-127896.

Full text
Abstract:
Purpose: To study the efficacy and side effects of humanized anti-CD19-CAR T-cell combined with multiple combination treatments in relapsed/refractory B-cell non-Hodgkin lymphoma. Methods: Thirty-eight relapsed/refractory B-cell non-Hodgkin lymphoma patients were enrolled in a clinical trial of anti-CD19 chimeric antigen receptor (CAR) modified T-cell expressing humanized anti-CD19 scFv and 4-1BB-CD3ζ costimulatory-activation domains therapy (ChiCTR1800018059) at the Department of Hematology in Tianjin First Center Hospital (Tianjin, China). Except for anti-CD19-CAR T-cell therapy, all the patients received multiple combination treatments before or at the same time of CAR-T cell therapy. The multiple combination treatments included anti-CD22-CAR T-cell, Programmed death 1 (PD-1) inhibitor, Bruton's tyrosine kinase (BTK) inhibitors, Lenalidomide, Advance high-dose chemotherapy and Radiotherapy. Patients were evaluated 2 months after the infusion. The side effects were observed in all the process of the combination treatments. Cytokine release syndrome (CRS) was graded according to the ASBMT Consensus Criteria. Results: The median time from infusion to cutoff day was 7 months (Range: 1 to 16 months). There were 37 patients included in the evaluation of the efficacy and side effects (Except for one patient with high tumor burden died of CRS 7 days after the infusion). The best overall response rate (ORR) was 75.6% (28/37). The complete response (CR) rate was 45.9% (17/37), the partail response (PR) rate was 29.7% (11/37), the stable disease (SD) rate was16.2% (6/37) and the disease progression (PD) rate was 8.1% (3/37). The grade of cytokine release syndrome (CRS) was Grade 1: 25/38, Grade 2: 9/38, Grade 3: 3/38, Grade 4: 0/38 and Grade 5: 1/38. Two patients died from disease progression within 60 days after infusion. One patient with high tumor burden who achieved PR at 14 days died from intestinal perforation after 25 days of infusion. The combination treatments of anti-CD22-CAR T-cell (4/38), treatment dose or 1/2 treatment dose of PD-1 inhibitor (5/38) or BTK inhibitors (3/38) therapy improved the curative effect of humanized anti-CD19-CAR T-cell therapy. Advance high-dose chemotherapy for patients (9/38) with high tumor burden before the anti-CD19-CAR T-cell therapy achived a satisfactory ORR (5/9) and Grade 1-2 CRS. No patients died from the advance and intensive chemotherapy. There were 6 patients with refractory lymphoma received radiotherapy before they enrolled in the anti-CD19-CAR T-cell therapy. There were 5 patients achived CR or PR except for one patient with high tumor burden died of CRS 7 days after the infusion (the IL-6 level was more than 1000 U/mL at day 3). But the side effects were significant in these 6 patients (Grade 1: 0/6, Grade 2: 2/6, Grade 3: 3/6, Grade 4: 0/6, Grade 5: 1/6). There was no efficacy improvement from the combination treatments of lenalidomide (14/38, 3 patients received advance high-dose chemotherapy meanwhile among the 14 patients), and the side effects were not significant. Conclusions: The multiple combination treatments combined with humanized anti-CD19-CAR T-cell therapy could improve the efficacy without increase side effects obviously. Disclosures No relevant conflicts of interest to declare.
APA, Harvard, Vancouver, ISO, and other styles
43

Joshi, Aishana. "The dawn of post antibiotic era: Are we prepared?" Journal of Kathmandu Medical College 4, no. 2 (May 31, 2016): 37–38. http://dx.doi.org/10.3126/jkmc.v4i2.15030.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Kant, Shashi, Sumeet Attri, Sita Thakur, and Ajay Sood. "Pregnancy outcome in women with intrahepatic cholestasis of pregnancy." International Journal of Research in Medical Sciences 8, no. 6 (May 26, 2020): 2232. http://dx.doi.org/10.18203/2320-6012.ijrms20202273.

Full text
Abstract:
Background: Intrahepatic cholestasis of pregnancy is a multifactorial condition of pregnancy diagnosed when otherwise unexplained pruritus with abnormal liver function test and neither of which has an alternative cause. The most appropriate gestational age for the delivery of women with ICP is yet to be determined. The present study is designed to determine whether with active intervention, pregnancy with ICP can be carried to a later gestation.Methods: Fifty Women with diagnosed a case of ICP were recruited into the study. The diagnosis of ICP was based on the symptoms, clinical examination and lab investigations. Group I: 25 women planned for delivery at POG 37 - 37+6 weeks of pregnancy. Group II: 25 women Planned for delivery at POG ≥38 weeks of pregnancy.Results: In group, one woman had preterm delivery at POG 36+2 weeks and rest of 24 women were delivered at POG 37-37+6 weeks. In group II, out of 25 women one woman had emergency LSCS at POG 35+3 weeks for MSL and induction of labour was done in 2nd for abnormal fetal well-being tests at POG 37 weeks. One woman had pre-term delivery at POG 36+1 weeks. Remaining 22 women in group II were delivered at POG ≥38 weeks. In the present study there was no significant difference in the gestational age at delivery between the two groups.Conclusions: It can be concluded that pregnancies with obstetric cholestasis can be carried to later gestation of ≥38 weeks under surveillance with UDCA treatment.
APA, Harvard, Vancouver, ISO, and other styles
45

"Author index volumes 37/38." Microelectronic Engineering 37-38 (November 1997): 589–99. http://dx.doi.org/10.1016/s0167-9317(97)80311-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

"Index to Volumes 37–38." Aliso 38, no. 1 (July 2021): 77–81. http://dx.doi.org/10.5642/aliso.20213801.06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

"Contents of Volumes 37 and 38." Journal of Symbolic Computation 38, no. 6 (December 2004): I—V. http://dx.doi.org/10.1016/s0747-7171(04)00108-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

"Index to Volumes 37 and 38." Journal of Symbolic Computation 38, no. 6 (December 2004): VI—X. http://dx.doi.org/10.1016/s0747-7171(04)00109-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

"Author index volumes 37 and 38." Journal of Pharmacological and Toxicological Methods 38, no. 4 (December 1997): 217–19. http://dx.doi.org/10.1016/s1056-8719(98)00009-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

"Subject index volumes 37 and 38." Journal of Pharmacological and Toxicological Methods 38, no. 4 (December 1997): 221–25. http://dx.doi.org/10.1016/s1056-8719(98)00010-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic '37-38' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography